Parathyroid hormone (1-36) - Novartis
Latest Information Update: 09 Aug 2002
At a glance
- Originator Novartis
- Class
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 11 Jul 1997 New profile
- 11 Jul 1997 Preclinical development for Postmenopausal osteoporosis in Switzerland (Parenteral)